Abstract:Hepatocellular carcinoma (HCC), one of the most common and lethal tumors worldwide, is usually not diagnosed until the disease is advanced, which results in ineffective intervention and unfavorable prognosis. Small molecule targeted drugs of HCC, such as sorafenib, provided only about 2.8 months of survival benefit, partially due to cancer stem cell resistance. There is an urgent need for the development of new treatment strategies for HCC. Tumor immunotherapies, including immune check point inhibitors, chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (BsAb), have shown significant potential. It is known that the expression level of glypican-3 (GPC3) was significantly increased in HCC compared with normal liver tissues. A bispecific antibody (GPC3-S-Fabs) was reported to recruit NK cells to target GPC3 positive cancer cells. Besides, bispecific T-cell Engagers (BiTE), including GPC3/CD3, an aptamer TLS11a/CD3 and EpCAM/CD3, were recently reported to efficiently eliminate HCC cells. It is known that immune checkpoint proteins programmed death-1 (PD-1) binding by programmed cell death-ligand 1 (PD-L1) activates immune checkpoints of T cells. Anti-PD-1 antibody was reported to suppress HCC progression. Furthermore, GPC3-based HCC immunotherapy has been shown to be a curative approach to prolong the survival time of patients with HCC in clinically trials. Besides, the vascular endothelial growth factor (VEGF) inhibitor may inhibit the migration, invasion and angiogenesis of HCC. Here we review the cutting-edge progresses on mechanisms and clinical trials of HCC immunotherapy, which may have significant implication in our understanding of HCC and its immunotherapy.

Clinical research progress on molecularly targeted therapy of primary hepatic carcinoma

Research Progress of MicoRNA in Molecular Targeting Treatment of Hepatocellular Carcinoma

Clinical Trials in Hepatocellular Carcinoma: an Update.

Research Progress of Targeted Therapy Combined with Immunotherapy for Hepatocellular Carcinoma

The advanced development of molecular targeted therapy for hepatocellular carcinoma

Molecular Targeted Therapy of HCC

Advances of Targeted Therapy for Hepatocellular Carcinoma

Research Advances in Systemic Therapy for Hepatocellular Carcinoma in the Era of Precision Medicine

Small-molecule-based targeted therapy in liver cancer

Advances in Clinical and Basic Research for Hepatocellular Carcinoma in China: a 2023 Review

Current Statuses of Molecular Targeted and Immune Checkpoint Therapies in Hepatocellular Carcinoma.

New advances in the treatment of intermediate and advanced hepatocellular carcinoma

Translational Medicine in Hepatocellular Carcinoma

Insights in Molecular Therapies for Hepatocellular Carcinoma

Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets

Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.

Advances in molecular biology and clinical practice of rectal liver metastases

Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances

Research Frontiers in Precision Therapy for Liver Cancer

The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy

Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy